Hepatitis Forums

Hepatitis C Main Forums => Hepatitis C Research News & Studies => Topic started by: Hep Editors on February 08, 2019, 11:00:51 am

Title: No Link Between Liver Cancer and Regimens That Include Hep C Drug Grazoprevir
Post by: Hep Editors on February 08, 2019, 11:00:51 am

People who take hepatitis C virus (HCV) regimens containing Merck’s grazoprevir, including as a component of Zepatier (grazoprevir/elbasvir), have a low rate of hepatocellular carcinoma (HCC, the most common form of liver cancer) during the following years. The authors of a recent analysis found no association between grazoprevir and the risk of liver cancer.

Presenting their findings at the Annual Meeting of the American Association for the Study of Liver Diseases in San Francisco (The Liver Meeting), researchers culled data from a long-term extension study of people with HCV who received a grazoprevir-containing regimen in the Phase II and III trials of the drug’s development program. The participants were followed from 24 weeks after treatment and made clinic visits every six months thereafter for up to five years.

For more...
https://www.hepmag.com/article/link-liver-cancer-regimens-include-hep-c-drug-grazoprevir